Reinier T. Hernandez

Optimized dosing of spatially heterogeneous radiopharmaceutical therapy reprograms poorly immunogenic tumors to enhance response to immune checkpoint blockade

This study shows that optimized spatially heterogeneous radiopharmaceutical therapy enhances immune checkpoint blockade response in poorly immunogenic tumors by promoting T cell activation and infiltration.

Low-dose radiopharmaceutical therapy enhances the efficacy of B7-H3 CAR T cells in murine metastatic neuroblastoma

This study shows that low-dose radiopharmaceutical therapy enhances the effectiveness of B7-H3 CAR T cells in treating metastatic neuroblastoma in mice.

Bispecific GD2xB7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma

This paper describes a bispecific antibody that targets GD2 and B7-H3 to improve tumor targeting and reduce toxicity in neuroblastoma treatment.

Intratumoral dose heterogeneity promotes adaptive anti-tumor immunity and predicts clinical response to radiopharmaceutical therapy

This study shows that heterogeneous radiation dose in tumors enhances anti-tumor immunity and correlates with better clinical outcomes in prostate cancer patients.

Tuning the Structural Properties of a Single-Domain Antibody Scaffold for Improved Fibroblast Activation Protein Targeting

This study engineers single-domain antibodies to improve targeting of FAP, showing that valency and molecular weight affect tumor uptake and biodistribution.

A MET-Targeted Variable New Antigen Receptor Theranostic for Non-Small Cell Lung Cancer

This paper develops a shark-derived VNAR-based theranostic agent for MET-altered NSCLC, showing imaging and therapeutic efficacy in preclinical models.

Priming versus propagating: distinct immune effects of an alpha- versus beta-particle emitting radiopharmaceutical when combined with immune checkpoint inhibition

This study compares the immune effects of alpha- and beta-particle emitting radiopharmaceuticals combined with immune checkpoint inhibitors in murine tumor models, finding distinct mechanisms of action based on radiation type.

Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors

This paper develops a bispecific antibody targeting GD2 and B7-H3 to improve tumor selectivity and reduce toxicity in GD2-positive tumors.

Low Dose Radiation by Radiopharmaceutical Therapy Enhances GD2 TRAC-CAR T Cells Efficacy in Localized Neuroblastoma

This paper shows that low-dose radiopharmaceutical therapy enhances GD2 TRAC-CAR T cell efficacy in neuroblastoma by improving tumor regression and immune response.

Effects of clinically relevant radionuclides on the activation of a type I interferon response by radiopharmaceuticals in syngeneic murine tumor models

This study examines how different radionuclides affect the type I interferon response in tumor models and shows that 225Ac enhances immunotherapy response via STING-dependent mechanisms.

Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library

The paper develops FAP-targeted theranostics using VNARs from a shark antibody library, showing high affinity and efficacy in vitro and in vivo.

Bispecific GD2 x B7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma